Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lexicon Pharmaceuticals' LX4211, a sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, along with the dipeptidyl peptidase 4 (DPP-4) inhibitor- sitagliptin (Januvia) has demonstrated top-line results in a clinical study.
Subscribe to our email newsletter
In the study, 18 patients with type 2 diabetis received single doses of either LX4211 (400 mg), sitagliptin (100 mg) or LX4211 plus sitagliptin on days 1, 8, or 15 to evaluate pharmacodynamic parameters, such as postprandial glucose (PPG), insulin, total and active glucagon-like peptide-1(GLP-1), PYY, and urinary glucose excretion (UGE).
The trial reported that single doses of LX4211 in combination with sitagliptin lowered blood glucose levels after meals (postprandial) when compared to treatment with sitagliptin alone.
Lexicon chief medical officer Pablo Lapuerta said LX4211 alone shows improvement in postprandial blood glucose and when combined, the two agents produce enhanced benefits on blood glucose, insulin, GLP-1 and PYY relative to sitagliptin alone.
Lexicon executive vice president and chief scientific officer Brian Zambrowicz said the new clinical results are backed by the earlier preclinical studies in mice that show a considerable increase in active GLP-1 after combination treatment with LX4211 and sitagliptin.